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SUMMARY. In chronic hepatitis C (CHC), treatment duration
may be individualized according to time to first undetectable
hepatitis C virus (HCV) RNA, with patients who attain
undetectable HCV RNA early in treatment being candidates
for shorter regimens. The aim of this study was to determine
the relapse rate in patients with CHC genotype (G) 1 infection
and low baseline viral load who achieved undetectable HCV
RNA byweek 4 [rapid virologic response (RVR)] when treated
for 24 weeks. This was an open-label, multicentre, nonin-
terventional study. Adult patients with G1 CHC infection and
baseline viral load <600,000 IU/mL who attained RVR were
treated with peginterferon alfa-2b (1.5 lg/kg/week) plus
ribavirin (800–1200 mg/day) for 24 weeks, then followed
for a further 24 weeks. The primary endpoint was relapse
rate, defined as the proportion of patients with undetectable
HCV RNA at treatment week 24 and detectable HCV RNA at
week 24 follow-up. The secondary efficacy endpoint was
sustained virologic response (SVR). Overall, 170 patients
were included in the efficacy-evaluable population. The
relapse rate was 9.7% (16/165, 95% confidence interval:
0.06–0.15), and SVR was attained by 149 of 170 patients
(87.6%). Virologic outcomes were consistent regardless of
age, gender, body weight and genotype. Seven patients
reported treatment-emergent serious adverse events (AEs),
and four patients discontinued treatment because of an AE.
This study further demonstrates that peginterferon alfa-2b
plus weight-based ribavirin for 24 weeks is an effective
treatment strategy for treatment-naive patients with G1 CHC
and low viral load who attain RVR.
Keywords: hepatitis C virus genotype, peginterferon, relapse,
ribavirin, viral load.
INTRODUCTION
An increase in relapse rate is the principal concern when
reducing treatment duration in patients infected with G1
CHC. Shortening duration of treatment reduces the
on-treatment period during which hepatitis C virus (HCV)
RNA is undetectable and increases the risk of post-treatment
relapse [1]. The relationship between on-treatment duration
of undetectable HCV RNA and treatment outcome has thus
become an important factor in defining treatment regimens
in the era of response-guided therapy [2]. Low viral load
prior to commencing treatment can also mitigate the risk of
relapse associated with a shortened treatment duration
strategy and is considered a favourable prognostic factor in
the treatment of patients with G1 CHC [3–5].
In patients with chronic hepatitis C G1 infection, short-
ened treatment strategies have been extensively evaluated
[4,6–9]. An earlier study to test this hypothesis was reported
by Zeuzem et al. in 2006. This study showed that in G 1
treatment-naive patients with a pretreatment baseline viral
Abbreviations: HCV, hepatitis C virus; SVR, sustained viral response;
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load £600 000 IU/mL who achieved undetectable HCV RNA
after 4 weeks [rapid virologic response (RVR)], treatment
duration could be shortened from the standard 48 weeks to
24 weeks without any significant decline in sustained viro-
logic response (SVR) or increase in relapse (SVR, 85% vs
89%; relapse, 8% vs 8%) [10].
The study by Zeuzem et al. formed the basis for the
approval of peginterferon (PEG-IFN) alfa-2b plus weight-
based ribavirin therapy for a period of 24 weeks in treat-
ment-naive patients with G1 infection and low baseline viral
load who attain RVR by the European Medicines Evaluation
Agency [11], a strategy that has also been subsequently
adopted for PEG-IFN alfa-2a plus ribavirin [12]. However,
because the study by Zeuzem et al. was a noncomparative,
historical control study using a highly selected patient
cohort [treatment-naive patients from the study by Manns
et al. [13] who were selected on the basis of tolerability,
compliance and adherence], further supporting evidence
was also deemed necessary. The aim of the current study
was therefore to determine the relapse rate in patients with
chronic hepatitis C G1 infection and favourable predictors of
responsiveness (low baseline viral load and undetectable
HCV RNA by week 4) when receiving PEG-IFN alfa-2b plus
ribavirin therapy for a total of 24 weeks in a situation akin
to real-life practice at experienced referral centres.
MATERIALS AND METHODS
Patients
Adult patients with chronic hepatitis C G1 infection and with
a baseline viral load <600 000 IU/mL prior to starting
treatment were enrolled and followed according to the
standard diagnostic and treatment policies of each site.
However, patients who had received any previous treatment
for chronic hepatitis C, women who were pregnant or
planning to become pregnant and the sexual partners of
women who intended to become pregnant were excluded.
Study design
This was an open-label, nonrandomized, multinational,
multicentre, noninterventional study (NCT00709228).
Mercks approach to the conduct of clinical trials is in accor-
dance with the ethical principles that have their origin in the
Declaration of Helsinki and that are consistent with Good
Clinical Practice and the applicable regulatory requirements.
All patients received PEG-IFN alfa-2b (1.5 lg/kg/
week) plus ribavirin (800–1200 mg/day) administered
according to patient body weight. Patients weighing £64 kg
received ribavirin 800 mg/day, patients weighing 65–85 kg
received 1000 mg/day and those weighing >85 kg received
1200 mg/day. Treatment duration was 24 weeks and all
patients were then followed for a further 24 weeks after
completing therapy.
All patients were required to have undetectable HCV RNA
at treatment week 4 to be enrolled in the study. Patients who
maintained undetectable HCV RNA at treatment week 24
were given the option to stop therapy with the agreement of
the investigator and were followed for 24 weeks post-treat-
ment. These patients were included in the efficacy analysis.
Patients who opted to continue therapy received treatment
outside of the study protocol, were censored as treatment
failures and were excluded from the efficacy-evaluable pop-
ulation. Patients with detectable HCV RNA at treatment week
4 also continued to receive treatment outside of the study
protocol. Quantitative PCR testing of HCV RNA was per-
formed at treatment weeks 4 and 24 and at week 24 of follow-
up at local laboratories; results were reported in IU/mL.
Study endpoints
The primary endpoint was the relapse rate, defined as the
proportion of patients with undetectable HCV RNA at
treatment week 24 to detectable HCV RNA at week 24 fol-
low-up. Patients who were identified as relapsers at the end
of the follow-up phase were offered re-treatment with PEG-
IFN alfa-2b plus ribavirin 800–1400 mg/day for an addi-
tional 48 weeks. The secondary efficacy endpoint was SVR,
defined as the percentage of patients with undetectable HCV
RNA at the end of the 24-week treatment period and at week
24 of follow-up.
Clinical assessment and review of laboratory data were
used to monitor safety and tolerability of study drugs in
accordance with routine clinical practice. Only data
regarding serious adverse events (SAEs; as defined using the
modified World Health Organization grading system) were
collected.
The all-enrolled population included all patients who
received at least one dose of study medication and who had
undetectable HCV RNA at week 4 of treatment. Efficacy
analyses were performed on the efficacy-evaluable population,
which included all patients in the all-enrolled population
who had undetectable HCV RNA at the end of 24 weeks of
treatment and stopped treatment after 24 weeks. For anal-
ysis of relapse rates, patients also needed to have nonmissing
HCV RNA assessment at 24 weeks of follow-up (an earlier
detectable HCV RNA during the follow-up phase was carried
forward to 24 weeks of follow-up visit). The primary safety
analysis is presented for the all-enrolled population.
The per-protocol population consisted of all patients in the
efficacy-evaluable population who did not have major pro-
tocol violations and who attended scheduled week-4, -12
and -24 visits and week-24 follow-up visit. For the purpose
of assessing the effect of adherence on relapse and SVR in the
per-protocol population, adherence was defined as patients
who received at least 80% of the planned treatment for at
least 80% of the scheduled treatment duration (80:80:80),
as verified by review of patients charts. Treatment adherence
was monitored by the investigator by tracking and recording
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the prescribed treatment regimen, date of administration and
dosing.
Statistics
The study was planned to enrol 150 patients with unde-
tectable HCV RNA at treatment week 4, to ensure 126
patients who would stop treatment with undetectable HCV
RNA at treatment week 24 and have virology results at
week 24 of follow-up (the efficacy-evaluable population).
Assuming a relapse rate of 9% [10], a sample population of
126 subjects would permit the estimation of relapse rate
within ±5% by using 95% confidence intervals (CIs). The
primary and secondary endpoints were summarized, and the
corresponding 95% CIs were calculated using the Clopper–
Pearson method.
RESULTS
Patient characteristics
In total, 187 patients met eligibility criteria and were
enrolled in the study (the all-enrolled population), and of
these 14 patients failed to complete the 24-week treatment
duration (Fig. 1). The remaining 173 patients completed
treatment, and 169 patients entered the post-treatment
follow-up.
Because of the noninterventional nature of this study
(treatment was administered in accordance with the product
label, and treatment assignment was directed according to
current clinical practice with no additional diagnostic or
monitoring procedures), there was no protocol-mandated
criterion for the sensitivity of the HCV RNA assays employed
at the local laboratories. As a result, evaluation of the 187
enrolled patients was based on local laboratory assays with
lower limits of detection (LLD) that ranged widely from 9.6
to 700 IU/mL, with most sites using assays with an LLD of
<60 IU/mL. In total, HCV RNA levels for 84% of patients
(157 of 187) were evaluated using assays with an LLD
£60 IU/mL; the remaining 16% of patients (30 of 187) were
evaluated with less sensitive assays ranging between 100
and 700 IU/mL.
Virologic outcomes
Overall, 170 patients from 14 European countries (Croatia,
France, Germany, Greece, Israel, Italy, Norway, Portugal,
Russia, Slovenia, Spain, Sweden, the Netherlands and Uni-
ted Kingdom) were included in the efficacy-evaluable pop-
ulation (Table 1). The relapse rate was 9.7% (16/165, 95%
CI: 0.06–0.15), and SVR was attained by 149 of 170
patients (87.6%) (Fig. 2). Relapse and SVR rates in the per-
protocol population and for patients in the per-protocol
population who were 80:80:80 adherent are shown in
Fig. 3.
An ad hoc analysis was conducted to evaluate the effect of
varying the sensitivity of assay used to evaluate week 4 HCV
RNA levels on relapse and SVR rates. When the analysis was
restricted to patients with treatment week 4 HCV RNA levels
evaluated using an assay with an LLD of £60 IU/mL, the
relapse rate was 6.4% (nine of 140) and the SVR rate was
91.6% (131/143). However, in patients evaluated at week 4
with a less sensitive assay (LLD >60 IU/mL), the relapse rate
was 28% (seven of 25) and the SVR rate was 66.7% (18 of
27).
Virologic outcomes were generally similar among male
and female patients and among younger and older patients
(Table 2). Relapse was numerically lower in patients
weighing >65–75 kg (ribavirin dose: 1000 mg/day) and
>85–105 kg (ribavirin dose: 1200 mg/day) compared with
patients weighing £65 kg and >75–85 kg; however, these
differences did not reach statistical significance (P = 0.19 for
both comparisons). Likewise, although SVR was numerically
higher and relapse lower in patients with genotype 1a
Screened
N = 496
PEG-IFN alfa-2b (1.5 μg/kg/week) 
+ ribavirin (800–1200 mg/day)
n = 482
Enrolled
n = 187
Not enrolled, n = 295
• Failure to meet eligibility criteria, n = 281
Discontinued treatment, n = 14
• Lost to follow-up, n = 5
• Adverse events, n = 4
• Did not wish to continue, n = 3
• Ineligible, n = 2
Discontinued follow-up, n = 5
• Lost to follow-up, n = 3
• Noncompliance, n = 1
• Administrative, n = 1
Completed 
treatment
n = 173
Did not enter follow-up 
n = 4*
Entered follow-up
n = 169
Completed follow-up
n = 164
Fig. 1 Patient disposition. *Includes one patient with
undetectable hepatitis C virus RNA at week 24 who was
included in the efficacy-evaluable population. This patient
had missing follow-up data, was classified as a nonre-
sponder and was not included in the relapse analysis.
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compared with those with genotype 1b infection, there were
no significant differences between the G1 subtypes (SVR:
93.3% vs 84.9%, P = 0.19; relapse: 6.7% vs 11.8%, P =
0.56).
Safety and tolerability
Treatment-emergent SAEs were reported in seven patients
(thrombosis, hypothyroidism, aggressive behaviour, pan-
creatitis, suicide attempt, neck abscess and personality dis-
order). In addition, one nontreatment-emergent SAE of acute
psychosis occurred during the follow-up phase, ‡30 days
after completing treatment.
Adverse events led to treatment discontinuations in four
patients: pancreatitis, thrombosis and aggressive behaviour
were considered SAEs, and one more patient discontinued
treatment because of disturbance in attention, which was
not considered an SAE (Table 3). Dose reductions or inter-
ruptions were required to manage 12 AEs in nine patients.
The most common AEs leading to dose reduction or inter-
ruption were neutropenia (n = 3), anaemia (n = 2) and
depression (n = 2); all other AEs were reported by one
Table 1 Patient characteristics
All-enrolled
patients (N = 187)
Male, n (%) 116 (62)
Race, n (%)
White 182 (97)
Asian 3 (2)
Black 1 (1)
Other 1 (1)
Age
Mean, years (SD) 37.8 (10.7)
18 to <40 years, n (%) 113 (60)
‡40 years, n (%) 74 (40)
Mean weight, kg (SD) 74.5 (14.2)
Genotype 1 subtype, n (%)
1a 50 (27)
1b 116 (62)
Unspecified 21 (11)
Mean duration of exposure,
years (SD)
13.2 (10.7)
Source of exposure
Parenteral 103 (55)
Sporadic 48 (26)
Transfusion 24 (13)
Other 12 (6)
SD, standard deviation.
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Fig. 2 Relapse and sustained virologic response rates in the
efficacy-evaluable population.
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(0.85, 0.95)
Fig. 3 Per-protocol analyses.
Table 2 subgroup analyses
Relapse (n = 165)* SVR (n = 170)
Gender, n (%)
Male 10/100 (10.0) 90/102 (88.2)
Female 6/65 (9.2) 59/68 (86.8)
Age, n (%)
<40 years 8/97 (8.2) 89/101 (88.1)
‡40 years 8/68 (11.8) 60/69 (87.0)
Body weight, n (%)
£65 kg 6/47 (12.8) 41/49 (83.7)
>65–75 kg 3/40 (7.5) 37/41 (90.2)
>75–85 kg 6/47 (12.8) 41/48 (85.4)
>85–105 kg 1/28 (3.6) 27/29 (93.1)
>105 kg 0/3 (0) 3/3 (100)
Subtype, n (%)
1a 3/45 (6.7)§ 42/45 (93.3)–
1b 12/102 (11.8) 90/106 (84.9)
Unspecified 1/18 (5.6) 17/19 (89.5)
*Follow-up data were not available for five patients in the
efficacy-evaluable population. Comparison between £65 kg
and >65–75 kg or >85–105 kg, Fishers exact test
P = 0.19. Comparison between >75–85 kg and >65–
75 kg or >85–105 kg, Fishers exact test P = 0.19. §Com-
parison between genotype 1a and genotype 1b, Fishers
exact test P = 0.56. –Comparison between G1a and G1b,
Fishers exact test P = 0.19. SVR, sustained virologic
response.
 2011 Blackwell Publishing Ltd
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patient each (bronchitis, decreased haemoglobin, headache
and dyspnoea). Treatment was also interrupted in the
patient with an SAE of neck abscess. There were no deaths
during the study period.
DISCUSSION
This study confirms that 24 weeks of therapy with PEG-IFN
alfa-2b plus weight-based ribavirin is sufficient to achieve
high rates of SVR in treatment-naive patients with chronic
hepatitis C G1 infection who have low viral load at baseline
and attain a RVR.
Several previous studies have also examined a 24-week
treatment strategy in G1 patients who attain RVR, and data
from the present study are generally consistent with previ-
ous observations [4,7,10]. Zeuzem et al. reported an SVR
rate of 89% and relapse rate of 8% in G1 patients with
baseline viral load <600 000 IU/mL, which compared
favourably with data derived from a historical control pop-
ulation treated for 48 weeks in which 85% of patients
attained SVR and relapse rate was also 8% [10]. Similarly,
Ferenci et al. and Mangia et al. have also reported favourable
rates of SVR in G1 patients with RVR treated for 24 weeks,
with both studies also indicating improved outcomes in the
cohort of patients with low baseline viral load [4,7]. Recent
data from the INDIV-2 study, where treatment was indi-
vidualized according to the time to first undetectable HCV
RNA, also confirm a favourable comparison of 24 weeks
with 48 weeks of therapy in patients with G1 infection with
baseline viral load <800 000 IU/mL who attained RVR. In
patients who received 24 weeks of treatment, 88% attained
SVR compared with 93% of patients who received 48 weeks
of therapy [14].
The subgroup analyses reported in the present study are
consistent with data derived from the large ‘‘real-life’’
cohort enrolled in the PROBE study, which also reported
that SVR rates were lower among patients with G1b
infection compared with G1a [15]. In the PROBE study,
SVR rates were 44% in patients with G1a infection and
37% in those with G1b infection when treated with PEG-
IFN alfa-2a or alfa-2b plus ribavirin. In logistic regression
analysis, SVR was significantly more likely in G1a patients
[odds ratio (OR): 1.36; 95% CI: 1.00–1.86; P = 0.05].
However, Jensen et al. reported that patients with G1b
infection were more likely to attain RVR than those with
G1a infection (OR: 1.8; 95% CI: 0.9–3.7; P = 0.095). In
logistic regression analysis, a baseline viral load
£200 000 IU/mL was an independent predictor of RVR
among G1a patients (OR: 5.9; P = 0.0015), whereas a
baseline viral load £600 000 IU/mL was significantly
associated with RVR in G1b patients (OR: 10.3; P <
0.0001). Interestingly, within the group of patients with
baseline viral load between 500 000 and 1 million copies/
mL, RVR was attained by 12% of those with G1a and
40% of those with G1b [16].
Weight-based ribavirin is an established component of
treatment for G1 chronic hepatitis C, with several studies
showing a strong association between ribavirin dose per
kilogram of body weight and SVR [13,17]. Shiffman et al.
reported that increasing the ribavirin dose significantly
increased the SVR rates from 19 to 29% in patients receiving
ribavirin 13.3 mg/kg/day to 49% in those receiving
15.2 mg/kg/day, with the increase in SVR occurring sec-
ondary to a reduction in relapse (8% vs 36–40%; P < 0.05)
[18]. In the present study, SVR rates were lower and relapse
rates higher in the subgroups of patients weighing £65 kg
and also those weighing >75–85 kg. Importantly, patients
weighing >75–85 kg received a daily ribavirin dose of
1000 mg, which equates to dose per kilogram bodyweight of
between 11.8 and 13.3 mg/kg/day, clearly falling in the
dose range considered suboptimal according to Shiffmans
data. This is in contrast to the patients with a lower body-
weight of >65–75 kg but who received the same ribavirin
dose of 1000 mg/day and, consequently, in whom the dose
per kilogram bodyweight was much higher (equivalent to
13.3–15.4 mg/kg/day). These data suggest that ribavirin
dosing in the 75–85 kg patient group in this study was
suboptimal and thus support the recent change in approval
status of Rebetol (Schering–Plough Corporation, now
Merck & Co., Inc., Whitehouse Station, NJ, USA) at a dose of
1200 mg/day for patients with bodyweight 81–85 kg
(increasing dose per unit bodyweight to 14.1–14.8 mg/kg in
this population) [19].
In conclusion, this study is consistent with the report by
Zeuzem et al., indicating that PEG-IFN alfa-2b (1.5 lg/kg/
week) plus weight-based ribavirin (800–1200 mg/day) for
24 weeks is an effective and sufficient treatment strategy
for treatment-naive patients with G1 chronic hepatitis C
with baseline viral load <600 000 IU/mL who attain RVR.
Using a sensitive HCV RNA assay (<60 IU/mL) for the
Table 3 Adverse events (AEs)
All-enrolled
patients (N = 187)
Adverse events leading to
study discontinuation, n (%)
4 (2)*
Adverse events leading to
dose reduction/interruption, n (%)
9 (5)
Serious AEs, n (%) 8 (4)
*Pancreatitis, thrombosis, aggressive behaviour and distur-
bance in attention. 12 events [neutropenia (n = 3), anae-
mia (n = 2), depression (n = 2), neck abscess, bronchitis,
decreased haemoglobin, headache and dyspnoea (n = 1
each)] in nine patients. Hypothyroidism, pancreatitis, neck
abscess, acute psychosis, aggression, personality disorder,
suicide attempt and thrombosis. Acute psychosis occurred
‡30 days after completion of treatment and was classified
nontreatment-emergent.
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evaluation of viremia at week 4 is an important element
when considering a reduced treatment duration for patients
with G1 HCV infection; use of a less sensitive assay should
be avoided because of the elevated risk of post-treatment
relapse.
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